|
1
|
Maurer M, Weller K, Bindslev-Jensen C,
Giménez-Arnau A, Bousquet PJ, Bousquet J, Canonica GW, Church MK,
Godse KV, Grattan CE, et al: Unmet clinical needs in chronic
spontaneous urticaria. A GA2LEN task force report.
Allergy. 66:317–330. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zuberbier T, Aberer W, Asero R, Abdul
Latiff AH, Baker D, Ballmer-Weber B, Bernstein JA, Bindslev-Jensen
C, Brzoza Z, Buense Bedrikow R, et al Endorsed by the following
societies, : AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI,
ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST,
EAACI, EIAS, EDF, EMBRN, ESCD, GA2LEN, IAACI, IADVL,
JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC,
SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO: The
EAACI/GA2LEN/EDF/WAO guideline for the definition,
classification, diagnosis and management of urticaria. Allergy.
73:1393–1414. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zuberbier T, Balke M, Worm M, Edenharter G
and Maurer M: Epidemiology of urticaria: A representative
cross-sectional population survey. Clin Exp Dermatol. 35:869–873.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bernstein JA, Lang DM, Khan DA, Craig T,
Dreyfus D, Hsieh F, Sheikh J, Weldon D, Zuraw B, Bernstein DI, et
al: The diagnosis and management of acute and chronic urticaria:
2014 update. J Allergy Clin Immunol. 133:1270–1277. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gaig P, Olona M, Muñoz Lejarazu D,
Caballero MT, Domínguez FJ, Echechipia S, García Abujeta JL,
Gonzalo MA, Lleonart R, Martínez Cócera C, et al: Epidemiology of
urticaria in Spain. J Investig Allergol Clin Immunol. 14:214–220.
2004.PubMed/NCBI
|
|
6
|
Maurer M, Abuzakouk M, Bérard F, Canonica
W, Oude Elberink H, Giménez-Arnau A, Grattan C, Hollis K, Knulst A,
Lacour JP, et al: The burden of chronic spontaneous urticaria is
substantial: Real-world evidence from ASSURE-CSU. Allergy.
72:2005–2016. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Magerl M, Altrichter S, Borzova E,
Giménez-Arnau A, Grattan CE, Lawlor F, Mathelier-Fusade P, Meshkova
RY, Zuberbier T, Metz M, et al: The definition, diagnostic testing,
and management of chronic inducible urticarias - The EAACI/GA(2)
LEN/EDF/UNEV consensus recommendations 2016 update and revision.
Allergy. 71:780–802. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maxim E, Aksut C, Tsoi D and Dellavalle R:
Global burden of urticaria: Insights from the 2016 Global Burden of
Disease Study. J Am Acad Dermatol. 79:567–569. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saini S, Rosen KE, Hsieh HJ, Wong DA,
Conner E, Kaplan A, Spector S and Maurer M: A randomized,
placebo-controlled, dose-ranging study of single-dose omalizumab in
patients with H1-antihistamine-refractory chronic idiopathic
urticaria. J Allergy Clin Immunol. 128:567–573.e1. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maurer M, Altrichter S, Bieber T,
Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J,
Hunzelmann N, Jakob T, et al: Efficacy and safety of omalizumab in
patients with chronic urticaria who exhibit IgE against
thyroperoxidase. J Allergy Clin Immunol. 128:202–209.e5. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saini SS, Bindslev-Jensen C, Maurer M,
Grob JJ, Bülbül Baskan E, Bradley MS, Canvin J, Rahmaoui A,
Georgiou P, Alpan O, et al: Efficacy and safety of omalizumab in
patients with chronic idiopathic/spontaneous urticaria who remain
symptomatic on H1 antihistamines: A randomized, placebo-controlled
study. J Invest Dermatol. 135:67–75. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maurer M, Rosén K, Hsieh HJ, Saini S,
Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A,
et al: Omalizumab for the treatment of chronic idiopathic or
spontaneous urticaria. N Engl J Med. 368:924–935. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaplan A, Ledford D, Ashby M, Canvin J,
Zazzali JL, Conner E, Veith J, Kamath N, Staubach P, Jakob T, et
al: Omalizumab in patients with symptomatic chronic
idiopathic/spontaneous urticaria despite standard combination
therapy. J Allergy Clin Immunol. 132:101–109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao ZT, Ji CM, Yu WJ, Meng L, Hawro T,
Wei JF and Maurer M: Omalizumab for the treatment of chronic
spontaneous urticaria: A meta-analysis of randomized clinical
trials. J Allergy Clin Immunol. 137:1742–1750.e4. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maurer M, Metz M, Brehler R, Hillen U,
Jakob T, Mahler V, Pföhler C, Staubach P, Treudler R, Wedi B, et
al: Omalizumab treatment in patients with chronic inducible
urticaria: A systematic review of published evidence. J Allergy
Clin Immunol. 141:638–649. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Metz M, Altrichter S, Ardelean E, Kessler
B, Krause K, Magerl M, Siebenhaar F, Weller K, Zuberbier T and
Maurer M: Anti-immunoglobulin E treatment of patients with
recalcitrant physical urticaria. Int Arch Allergy Immunol.
154:177–180. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Metz M, Bergmann P, Zuberbier T and Maurer
M: Successful treatment of cholinergic urticaria with
anti-immunoglobulin E therapy. Allergy. 63:247–249. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Metz M, Schütz A, Weller K, Gorczyza M,
Zimmer S, Staubach P, Merk HF and Maurer M: Omalizumab is effective
in cold urticaria-results of a randomized placebo-controlled trial.
J Allergy Clin Immunol. 140:864–867.e5. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Boyce JA: Successful treatment of
cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin
Immunol. 117:1415–1418. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Güzelbey O, Ardelean E, Magerl M,
Zuberbier T, Maurer M and Metz M: Successful treatment of solar
urticaria with anti-immunoglobulin E therapy. Allergy.
63:1563–1565. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bullerkotte U, Wieczorek D, Kapp A and
Wedi B: Effective treatment of refractory severe heat urticaria
with omalizumab. Allergy. 65:931–932. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Krause K, Ardelean E, Kessler B, Magerl M,
Metz M, Siebenhaar F, Weller K, Worm M, Zuberbier T and Maurer M:
Antihistamine-resistant urticaria factitia successfully treated
with anti-immunoglobulin E therapy. Allergy. 65:1494–1495. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maurer M, Schütz A, Weller K, Schoepke N,
Peveling-Oberhag A, Staubach P, Müller S, Jakob T and Metz M:
Omalizumab is effective in symptomatic dermographism - results of a
randomized placebo-controlled trial. J Allergy Clin Immunol.
140:870–873.e5. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bindslev-Jensen C and Skov PS: Efficacy of
omalizumab in delayed pressure urticaria: A case report. Allergy.
65:138–139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zuberbier T, Aberer W, Asero R,
Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF,
Giménez-Arnau A, Godse K, et al: European Academy of Allergy and
Clinical Immunology; Global Allergy and Asthma European Network;
European Dermatology Forum; World Allergy Organization: The
EAACI/GA(2) LEN/EDF/WAO Guideline for the definition,
classification, diagnosis, and management of urticaria: The 2013
revision and update. Allergy. 69:868–887. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weller K, Groffik A, Church MK, Hawro T,
Krause K, Metz M, Martus P, Casale TB, Staubach P and Maurer M:
Development and validation of the Urticaria Control Test: a
patient-reported outcome instrument for assessing urticaria
control. J Allergy Clin Immunol. 133:1365–1372.e1-6. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Młynek A, Zalewska-Janowska A, Martus P,
Staubach P, Zuberbier T and Maurer M: How to assess disease
activity in patients with chronic urticaria? Allergy. 63:777–780.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Syrigos N, Grapsa D, Zande M, Tziotou M
and Syrigou E: Treatment response to omalizumab in patients with
refractory chronic spontaneous urticaria. Int J Dermatol.
57:417–422. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rorie A and Gierer S: A case of aquagenic
urticaria successfully treated with omalizumab. J Allergy Clin
Immunol Pract. 4:547–548. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sussman G, Hébert J, Barron C, Bian J,
Caron-Guay RM, Laflamme S and Stern S: Real-life experiences with
omalizumab for the treatment of chronic urticaria. Ann Allergy
Asthma Immunol. 112:170–174. 2014. View Article : Google Scholar : PubMed/NCBI
|
